Hemodialysis.-Induced Hypotension Therapy for End Stage Kidney Disease

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 27, 2022

Primary Completion Date

December 30, 2024

Study Completion Date

August 31, 2025

Conditions

Hemodialysis ComplicationHypotension of Hemodialysis

Interventions

DRUG

Lanadelumab Injection [Takhzyro]

Lanadelumab 300 mg subcutaneous injection

DRUG

Placebo

Placebo injection

Trial Locations (1)

Vanderbilt University Medical Center, Nashville

All Listed Sponsors

lead

Vanderbilt University Medical Center

OTHER